ClinicalTrials.gg
RecruitingNCT04921943Updated Oct 20, 2026

Hypertonic Saline for MAC

A Phase 4 interventional study of Hypertonic saline and Azithromycin in Nontuberculous Mycobacterial Lung Disease and Nontuberculous Mycobacterium Infection, sponsored by Oregon Health and Science University. Recruiting at 3 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-20.

Sponsored by Oregon Health and Science University · Phase 4, Interventional, and Treatment

How we know

From the registry’s dates

  • Started May 2021; still recruiting 5 years 6 months later.
Updated Oct 20, 2026Site recruiting status changedPrimary completion moved+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
50
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 24 studies in Mycobacterium Infections, Nontuberculous with a site in United States — 7 open to participants now, 7 under way, none of them phase 3. Mycobacterium Infections, Nontuberculous · United States.

Planned enrollment
11th of 18
50 · median 58
Started
2021
with 3 others
Phase 4
Only one
of the 24
Registered
19th of 24
by date

Among the 24 studies in Mycobacterium Infections, Nontuberculous with a site in United States, this one is the 11th largest by planned enrollment of the 18 interventional ones that give a count, is one of 4 that started in 2021, is the only one in phase 4, and was the 19th registered.

Mycobacterium Infections, Nontuberculous

54 studies on the registry are indexed under Mycobacterium Infections, Nontuberculous; 19 are open to participants now.

Browse Mycobacterium Infections, Nontuberculous studies →

Open to participants now

7 of the 24 studies in Mycobacterium Infections, Nontuberculous with a site in United States are open now. Recruiting first, the newest first:

1 more — sign in →

All 7 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 12 Mycobacterium Infections, Nontuberculous studies recruiting now, 8 (67%) set no upper age limit and 2 (17%) stop at 75 or younger; 4 take children under 18; 2 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 24 studies in Mycobacterium Infections, Nontuberculous with a site in United States, or all of them as a file.
02

Study summary

The MAC-HS study is a testing whether hypertonic saline helps improve symptoms and clearance of mycobacteria in patients with M. avium complex lung infections.

Read the detailed description

The MAC-HS study is an open label, randomized control trial of hypertonic saline in pulmonary M. avium complex patients. Eligible patients who consent to participate will be randomized 1:1 to hypertonic saline or standard of care for 12 weeks. All patients in the treatment group will take inhaled hypertonic saline twice daily for 12 weeks. Patients may continue with other airway clearance methods (i.e. flutter, acapella valve, aerobika, postural drainage, huff cough, percussion). Patients may also be treated with antibiotics targeted at other pathogens if an exacerbation occurs. Patients may also be actively treated with inhaled corticosteroid at the time of enrollment, with dosing adjustments during the trial discouraged. Patients with disease progression at any time can be discontinued from the study treatment and treated according to ATS/IDSA guidelines at the discretion of the primary investigator. However, such patients will still complete the 12 week final visit, sputum collection and AE assessment.

03

Conditions studied

  • Nontuberculous Mycobacterial Lung Disease
  • Nontuberculous Mycobacterium Infection
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • At least 2 positive MAC sputum cultures in the last 12 months with at least one AFB positive sputum obtained within 12 weeks prior to randomization
  • Meet American Thoracic Society (ATS)/ Infectious Disease Society of America (IDSA) 2007 pulmonary clinical disease criteria[1]
  • Age 18 and older
  • Diagnosis of Bronchiectasis and/or bronchiectatic findings evident on chest CT report
  • Ability to provide

Exclusion criteria

Exclusion Criteria:

  • Any patient who is unwilling or unable to provide consent or to comply with this protocol
  • Cavitary NTM disease
  • Patients who are currently taking or within the prior 6 months received any of the following: bedaquiline, or any component of ATS/IDSA multi-drug recommended therapy (macrolide, ethambutol, rifampin) for MAC treatment
  • Diagnosis of
  • Diagnosis of Cystic fibrosis
  • Active pulmonary tuberculosis, fungal, or nocardial disease requiring treatment at screening
  • Current use of chronic systemic at doses of 15 mg/day for more than 3 months
  • Prior lung or other solid organ transplant
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
50 participants (estimated)

Study arms

  • Experimental
    Hypertonic saline

    Patients who randomize to the hypertonic saline arm will be prescribed a nebulizer device to nebulize hypertonic saline (7%) twice daily for 12 weeks. Hypertonic saline (3%) can be prescribed in the case of poor tolerability of the 7% solution.

    Drug: Hypertonic saline

  • Active comparator
    Standard of Care

    Patients who randomize to the standard of care arm will receive treatment for pulmonary MAC based on the approved ATS/IDSA guidelines. Changes to standard of care regimen may be made based on the investigator's discretion.

    Drug: Azithromycin · Drug: Ethambutol · Drug: Rifampin

Interventions

  • DrugHypertonic saline

    Nebulizing with 7% hypertonic saline twice daily for 12 weeks.

  • Standard of care

  • Standard of care

  • Standard of care

06

What researchers measure

Primary outcomes

  1. Culture conversion

    At least two negative AFB cultures on different days.

    Time frame: 12 weeks

Secondary outcomes

  1. Semi-quantitative culture results

    Evaluate acid fast bacilli (AFB) smear results to see if there is a decreased mycobacterial load (i.e. AFB smear 4+ decreasing to 3+).

    Time frame: 12 weeks

07

Study locations

1 of 3 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Started May 2021 (actual). Primary completion is estimated for Jan 2027, 68 months after the start.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 20, 2026: primary completion Dec 2025 → Jan 2027 and completion Dec 2025 → Jan 2027.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jun 4, 2021
First posted
Jun 10, 2021
StartActual
May 18, 2021
Primary completionEst.
Jan 20, 2027was Dec 2025
CompletionEst.
Jan 20, 2027was Dec 2025
Last update
Oct 20, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
2 sites changed recruiting status (2 now completed)
Show 2 sites
  • NYU Langone Health · New York, United StatesActive, not recruiting→Completed
  • Oregon Health & Science University · Portland, United StatesRecruiting→Completed
Oct 20, 2026
Primary completion
Dec 31, 2025→Jan 20, 2027
Oct 20, 2026
Study completion
Dec 31, 2025→Jan 20, 2027
Oct 20, 2026
Site contacts
Changed at 1 site. See the sites
Show the site
  • Oregon Health & Science University · Portland, United StatesContact removed s•••@ohsu.edu · •••2136Contact removed j•••@ohsu.edu · •••2568Contact removed (no phone or email listed)
Oct 20, 2026
Show all 1 update
  1. Oct 20, 2026
    2 sites changed recruiting status (2 now completed)
    Show 2 sites
    • NYU Langone Health · New York, United StatesActive, not recruiting→Completed
    • Oregon Health & Science University · Portland, United StatesRecruiting→Completed
    Primary completion Dec 31, 2025→Jan 20, 2027
    Study completion Dec 31, 2025→Jan 20, 2027
    Site contacts Changed at 1 site. See the sites
    Show the site
    • Oregon Health & Science University · Portland, United StatesContact removed s•••@ohsu.edu · •••2136Contact removed j•••@ohsu.edu · •••2568Contact removed (no phone or email listed)
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT04921943
Collaborators
NTM Info & Research, Inc., University Health Network, Toronto, New York University
Responsible party
Kevin Winthrop (Principal Investigator, Oregon Health and Science University) — Principal investigator
First posted
Jun 10, 2021
Start date
May 18, 2021
Primary completion
Jan 20, 2027 (estimated)
Completion
Jan 20, 2027 (estimated)
Last update
Oct 20, 2026

Study contacts

Daniel Bouchat
Contact
johdanie@ohsu.edu
503-494-1859
Alyssa Schroeder
Contact
schroeder@ohsu.edu
503-494-2136

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion